Biotron Limited ( (AU:BIT) ) has issued an update.
Biotron Limited has initiated an Entitlement Issue to raise funds, securing $1,274,589 to support its antiviral program commercialization, including its lead asset BIT225, and to expand its Hepatitis B virus program. The company continues to collaborate with C14 Consulting Group LLC to refine its commercialization strategy and achieve strategic partnerships, leveraging data from recent clinical trials to drive business development.
More about Biotron Limited
Biotron Limited is a biotechnology company focused on the development and commercialization of antiviral programs. Its primary products include a portfolio of antiviral programs with a lead clinical asset, BIT225. The company is actively engaged in strategic partnerships to advance its antiviral initiatives, particularly in collaboration with the USA-based C14 Consulting Group LLC.
YTD Price Performance: 390.0%
Average Trading Volume: 2,000
Technical Sentiment Signal: Sell
Current Market Cap: $2.55M
See more data about BIT stock on TipRanks’ Stock Analysis page.